Latest Breaking News On - Chris min - Page 1 : vimarsana.com

Longeveron Inc (NASDAQ:LGVN) Q1 2023 Earnings Call Transcript

Operator: Good morning, and welcome to Longeveron s call today to discuss the company s 2023 First Quarter and Financial Results. All participants are currently in listen-only mode.

United statesJames clavijoMichael okunewitchMaxim groupNational heartLogicvision incLongeveron incBlood instituteCall transcript mayChief financial officerWa el hashadChief executive officerJoshua hareChief scientific officerChris minActing chief medical officer

Longeveron Inc Provides Corporate Update and Reports First Quarter 2023 Financial Results

12.05.2023 - - New long-term survival data disclosed from ELPIS I trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome; Data reinforce potential mortality benefit - - First patient dosed in Phase 2 clinical trial of Lomecel-BTM for Aging-Related Frailty .

United statesJames clavijoLongeveron incDrug administrationExchange commissionNational centerJuntendo university hospital tokyoStern ir incWa el hashadChief executiveAging related frailtyQuarter business updatesHypoplastic left heart syndromeFast trackRare pediatric diseaseOrphan drug designations

Longeveron Inc (NASDAQ:LGVN) Q4 2022 Earnings Call Transcript

Operator: Good morning, and welcome to Longeveron s call today to discuss the company s 2022 Fourth Quarter and Full Year Financial Results.

United statesMichael okunewitchJames clavijoNational centerMaxim groupJuntendo university hospitalLogicvision incLongeveron incCall transcript marchFull year financialChief financialFourth quarterFull yearWa el hashadChief executive officerChris min

Longeveron (LGVN) Announces Publication of Final Data from ELPIS I Trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome in Peer-Reviewed Journal

Longeveron (LGVN) Announces Publication of Final Data from ELPIS I Trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome in Peer-Reviewed Journal
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Sunjay kaushalDivision head of cardiovascularDrug administrationLongeveron or companyNational heartBlood instituteLongeveron incWall streetEuropean heart journalGlenn procedureEuropean heart journal openChris minInterim chief executive officerChief medicalDivision headCardiovascular thoracic surgery

Longeveron Announces Publication of Final Data from ELPIS I Trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome in Peer-Reviewed Journal

19.01.2023 - - Full results published in European Heart Journal Open - - Study met primary safety endpoint - - All patients alive, transplant-free, and maintained expected rate of growth one year after treatment - - Data supports ongoing clinical . Seite 1

United statesSunjay kaushalDivision head of cardiovascularLongeveron or companyLongeveron incEuropean heart journalGlenn procedureEuropean heart journal openChris minInterim chief executive officerChief medicalDivision headCardiovascular thoracic surgery